495
edits
Changes
Chromophobe renal cell carcinoma (view source)
Revision as of 11:29, 22 August 2016
, 11:29, 22 August 2016→References
== Contributors ==
== Contributors ==
Daynna Wolff PhD FACMG
Daynna Wolff, PhD FACMG
<br>
Yajuan Liu, PhD
Yajuan Liu, PhD
<br>
Rajyasree Emmadi, MD
Rajyasree Emmadi, MD
<br>
Banumathy Gowrishankar, PhD
Banumathy Gowrishankar, PhD
<br>
Jane Houldsworth, PhD
Jane Houldsworth, PhD
== Description ==
== Description ==
Chromophobe Renal Cell Carcinoma derives from the intercalated cells of the collecting duct epithelium and accounts for ~5% of renal tumors (Diaz JI, Mora LB, Hakam A. The Mainz Classification of Renal Cell Tumors. Cancer Control. 1999 Nov;6(6):571-579).
Chromophobe Renal Cell Carcinoma derives from the intercalated cells of the collecting duct epithelium and accounts for ~5% of renal tumors.<ref>Diaz JI, Mora LB, Hakam A. The Mainz Classification of Renal Cell Tumors. Cancer Control. 1999 Nov;6(6):571-579</ref>
== IHC Markers ==
== IHC Markers ==
! Chromosome !! Gain/Loss/Amp !! Region
! Chromosome !! Gain/Loss/Amp !! Region
|-
|-
|1 || Loss || Chr1
|1 || Loss || Chr1 (90%)
|-
|-
|2 || Loss || Chr2
|2 || Loss || Chr2 (80%)
|-
|-
|6 || Loss || Chr6
|3 || Loss || Chr3 (25%)
|-
|-
|10 || Loss || Chr10
|5 || Loss || Chr5 (20%)
|-
|-
|13 || Loss || Chr13
|6 || Loss || Chr6 (90%)
|-
|-
|17 || Loss || Chr17
|8 || Loss || Chr8 (15%)
|-
|-
|21 || Loss || Chr21
|9 || Loss || Chr9 (25%)
|-
|10 || Loss || Chr10 (90%)
|-
|11 || Loss || Chr11 (10%)
|-
|13 || Loss || Chr13 (85%)
|-
|17 || Loss || Chr17 (90%)
|-
|18 || Loss || Chr18 (15%)
|-
|21 || Loss || Chr21 (70%)
|}
|}
[[File:TCGA-chromophobe RCC.jpeg|center|900px|TCGA Chromophobe RCC copy number profile]]
== Rearrangements ==
== Rearrangements ==
[[TERT]] (upstream) (5p15) (12%)
[[TERT]] (upstream) (5p15) (12%)<ref name=davis>Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaipparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA; Cancer Genome Atlas Research Network, Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014 Sep 8;26(3):319-30.</ref>
== Mutations (SNV/INDEL) ==
== Mutations (SNV/INDEL) ==
=== From Cosmic Mutated in >20% ===
=== From Cosmic Mutated in >20%<ref>COSMIC (http://cancer.sanger.ac.uk/cosmic)</ref> ===
=== Mutated in 10-20% ===
=== Mutated in 10-20% ===
[[TP53]]
=== Mutated in 5-10% ===
=== Mutated in 5-10% ===
[[VHL]], [[PTEN]]
=== Mutated in 2-5% ===
=== Mutated in 2-5% ===
[[KMT2D]], [[KMT2C]], [[TERT]], [[MET]], [[ARID1A]], [[FAAH2]], [[PDHB]], [[PDXDC1]], [[ZNF765]]
=== mtDNA ===
=== mtDNA ===
== Epigenomics (methylation) ==
== Epigenomics (methylation) ==
epigenetic silencing of CDKN2A
== Main Pathways Involved ==
== Main Pathways Involved ==
MTOR pathway targeted (23% cases), increased expression of genes involved in oxidative phosphorylation
== Diagnosis ==
== Diagnosis ==
Overall loss of whole chormosomes, in particular of chromosomes 1, 2, 6, 10, 13, 17, and 21, eosinophilic variant is mostly diploid<ref>Speicher MR, Schoell B, du Manoir S, Schröck E, Ried T, Cremer T, Störkel S, Kovacs A, Kovacs G. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol. 1994 Aug;145(2):356-64.</ref>
== Prognosis ==
== Prognosis ==
Overall low risk of tumor progression, metastasis, and disease-specific death
== Therapeutics ==
== Therapeutics ==